Supporting
patients together
Providing patients with personalized, 1 on 1 support to help them access, start, and stay on track with their prescribed treatment plan.
US-MULT-230356
US-MULT-230356
Providing patients with personalized, 1 on 1 support to help them access, start, and stay on track with their prescribed treatment plan.
Writing a Formulary Exception Request Letter
Guidance and example of a formulary exception request letter
Submitting an Appeal Letter
Sample and instructions on submitting an appeal letter
HUMIRA Complete can help patients understand their insurance coverage and assist in identifying ways to save on HUMIRA.
Eligible commercially-insured patients can get HUMIRA for as little as $5 a month with the HUMIRA Complete Savings Card.
Help patients access the Savings Card:
*Eligibility: Available to patients with commercial insurance coverage for HUMIRA® (adalimumab) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit HUMIRASavingsCard.com or call 1.800.4HUMIRA for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie.
Accessing treatment
Field Access Specialists can provide education to address many access and reimbursement questions you may have. These trained professionals support healthcare office staff and their patients with insurance coverage and access issues. They can provide in-person background on HUMIRA Complete, including access and reimbursement support tools and resources for your patients’ unique financial situations.
Dedicated resources
HUMIRA Complete provides your patients with the resources they need when they need them, throughout their whole treatment journey.
Insurance Specialists will continue to help patients understand their insurance coverage and potential options to save on HUMIRA. Nurse Ambassadors† provide one-on-one support to help meet the unique needs of each individual patient. With an average of 19 years of nursing experience, Nurse Ambassadors are the heart of HUMIRA Complete.2
Nurse Ambassadors help with:
While patients will get their initial injection from a healthcare provider, a Nurse Ambassador can help reinforce training and provide ongoing support. Patients can choose from personalized training provided by a nurse or online training videos.
Direct your patients to step-by-step instruction videos for injecting HUMIRA.
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue HUMIRA if a patient develops a serious infection or sepsis.
Reported infections include:
Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.
HYPERSENSITIVITY
HEPATITIS B VIRUS REACTIVATION
NEUROLOGIC REACTIONS
HEMATOLOGIC REACTIONS
CONGESTIVE HEART FAILURE
AUTOIMMUNITY
IMMUNIZATIONS
ADVERSE REACTIONS
Please see Full Prescribing Information.
US-HUM-210183
References:
HUMIRA has >90% preferred national commercial and Medicare Part D formulary coverage under the pharmacy benefit as of January 20231*
*Preferred means HUMIRA is on a preferred tier or otherwise has preferred status on the plan’s formulary.
Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
Questions about access for your patients?
Learn more about how to help your patients access HUMIRA
1. Data on file, AbbVie Inc., January 2023.
US-HUM-220513
